Loading patent…
OwnerSeung Hyun Yooinventor
Estimating the term…
Compositions for inhibiting the aggregation of a granin from a non-toxic low molecular weight form to a toxic high molecular weight aggregated form and/or dissociating a high molecular weight aggregated form to a low molecular weight form are provided. Such a composition typically includes one or more active compounds or agents, which may also be referred to herein as disaggregation compounds. Using the compounds and compositions described herein, methods of i) modulating, inhibiting or preventing the interaction of granins with metal ions, ii) modulating, inhibiting, preventing the aggregation of granins or dissociating aggregated granins, iii) reducing or inhibiting cell toxicity, iv) treating or preventing dementia or Alzheimer's disease, and v) preventing or treating Parkinson's and/or Huntington's diseases are also provided.
A composition for inhibiting the aggregation of a granin from a low molecular weight form to a high molecular weight aggregated form, the composition comprising at least two of the following:
A composition for inhibiting the aggregation of a granin from a low molecular weight form to a high molecular weight aggregated form and/or dissociating a high molecular weight aggregated form to a low molecular weight form, the composition comprising i) an anthoxanthin selected from scutellarein, luteolin, baicalein, kaempferol, quercetin, apigenin, tangeretin, myricetin, fisetin, and ii) a stilbenoid selected from resveratrol, piceatannolin, pinosylvin, pterostilbene, astringin, piceid, iii) a flavan selected from epigallocatechin 3-gallate (EGCG), catechin, gallocatechin, catechin 3-gallate, gallocatechin 3-gallate, epicatechin, epigallocatechin, epicatechin 3-gallate, theaflavin-3-gallate, theaflavin-3′-gallate, theaflavin-3,3′-gallate, thearubigin, and proanthocyanidins. and iv) a compound selected from cordycepin, tyrphostin AG1478, and 5,7-dimethoxyflavone.
A composition for inhibiting the interaction of granins with metal ions, the composition comprising at least two of the following:
A composition for inhibiting the interaction of granins with metal ions, the composition comprising i) an anthoxanthin selected from scutellarein, luteolin, baicalein, kaempferol, quercetin, apigenin, tangeretin, myricetin, fisetin, morin, and ii) a stilbenoid selected from resveratrol, piceatannolin, pinosylvin, pterostilbene, astringin, piceid, iii) a flavan selected from epigallocatechin 3-gallate (EGCG), catechin, gallocatechin, catechin 3-gallate, gallocatechin 3-gallate, epicatechin, epigallocatechin, epicatechin 3-gallate, theaflavin-3-gallate, theaflavin-3′-gallate, theaflavin-3,3′-gallate, thearubigin, and proanthocyanidins. and iv) a compound selected from cordycepin, tyrphostin AG1478, and 5,7-dimethoxyflavone.
A pharmaceutical composition for the treatment or prevention of dementia or Alzheimer's disease comprising a composition for inhibiting the aggregation of a granin from a low molecular weight form to a high molecular weight aggregated form.
A pharmaceutical composition for the treatment or prevention of dementia or Alzheimers disease, the composition comprising at least two of the following:
A pharmaceutical composition for the treatment or prevention of dementia or Alzheimers disease, the composition comprising i) an anthoxanthin selected from scutellarein, luteolin, baicalein, kaempferol, quercetin, apigenin, tangeretin, myricetin, fisetin, morin, and ii) a stilbenoid selected from resveratrol, piceatannolin, pinosylvin, pterostilbene, astringin, piceid, iii) a flavan selected from epigallocatechin 3-gallate (EGCG), catechin, gallocatechin, catechin 3-gallate, gallocatechin 3-gallate, epicatechin, epigallocatechin, epicatechin 3-gallate, theaflavin-3-gallate, theaflavin-3′-gallate, theaflavin-3,3′-gallate, thearubigin, and proanthocyanidins. and iv) a compound selected from cordycepin, tyrphostin AG1478, and 5,7-dimethoxyflavone.
Dependencies are inferred from the claim text.